• Glaukos Corporation recently announced that the U.S. Centers for Medicare and Medicaid Services has granted Epioxa a unique, permanent HCPCS J-code (J2789) for keratoconus treatment, effective July 1, 2026, aimed at simplifying billing and reimbursement for providers.
• This permanent J-code assignment is important because it can make it easier for payers and clinicians to adopt Epioxa, potentially improving patient access to treatment for a frequently underdiagnosed, sight-threatening corneal disease.
• We’ll now examine how CMS’s permanent J-code for Epioxa could influence Glaukos’ investment narrative around reimbursement and product adoption.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Glaukos Investment Narrative Recap

To own Glaukos, you have to believe that interventional eye care and corneal therapies like Epioxa and iDose TR can justify today’s premium valuation despite ongoing losses and reimbursement sensitivity. CMS’s permanent J-code for Epioxa may help de risk near term reimbursement and adoption for its keratoconus franchise, but it does not eliminate the broader risks around pricing pressure, competition in glaucoma devices, or the company’s heavy spending relative to its current earnings profile.

The recent J-code decision for Epioxa ties directly into Glaukos’s 2026 net sales guidance of US$600 million to US$620 million, as smoother reimbursement could support the corneal segment that management is already counting on. It also sits alongside earlier milestones like the J-code for iDose TR and Epioxa’s FDA approval, reinforcing that reimbursement and procedural coding are central to the current catalyst story rather than an incremental side benefit.

However, investors should also be aware that reimbursement cuts or slower than expected adoption for Epioxa could...

Glaukos' narrative projects $1.0 billion revenue and $99.2 million earnings by 2029. This requires 26.1% yearly revenue growth and a $286.9 million earnings increase from -$187.7 million today.

Uncover how Glaukos' forecasts yield a $138.75 fair value, a 14% upside to its current price.

Exploring Other Perspectives

While consensus expects Glaukos revenue to grow about 19 percent annually, the most cautious analysts saw 2029 earnings at only US$55.5 million, highlighting how assumptions about reimbursement strength and corneal adoption can diverge sharply even before factoring in the new Epioxa J-code decision.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth as much as 99% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

No Opportunity In Glaukos?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.